Conditioned serum in vitro treatment of chondrocyte pellets and osteoarthritic explants.
Authors: Löfgren Maria, Ekman Stina, Ekholm Josefine, Engström Mona, Fjordbakk Cathrine T, Svala Emilia, Holm Forsström Karin, Lindahl Anders, Skiöldebrand Eva
Journal: Equine veterinary journal
Summary
# Editorial Summary: Conditioned Serum and Cartilage Health in Horses Autologous conditioned serum (ACS) is increasingly used in equine practice to manage osteoarthritis, yet robust evidence supporting its efficacy at the cellular level remains limited. Löfgren and colleagues conducted a rigorous in vitro investigation using two complementary models: chondrocyte pellet cultures stimulated with inflammatory cytokine IL-1β, and cartilage explants harvested from horses with established osteoarthritis, testing three serum preparations including standard pooled serum and ACS-conditioned variants over treatment periods of 2–24 days. Although conditioned serum preparations successfully elevated anti-inflammatory IL-1 receptor antagonist (IL-1Ra) concentrations compared to unconditioned serum, this did not translate into meaningful protection against IL-1β-driven catabolic responses; genes regulating cartilage matrix degradation remained upregulated, whilst structural cartilage molecules (aggrecan and collagen) were actually downregulated with conditioned serum treatment, and osteoarthritic explants showed no histological improvement over the 24-day study period. These findings suggest that the simple presence of elevated IL-1Ra in vitro is insufficient to halt the molecular cascade of cartilage damage, indicating that in vivo efficacy—if present—likely depends on additional biological mechanisms not captured by these cellular models. The results warrant cautious interpretation of ACS efficacy claims and highlight the critical gap between laboratory evidence and clinical outcomes; practitioners should consider these limitations when counselling clients on osteoarthritis management whilst awaiting higher-level clinical evidence.
Read the full abstract on PubMed
Practical Takeaways
- •Autologous conditioned serum did not provide the expected therapeutic benefit for osteoarthritis in these in vitro models, raising questions about clinical efficacy claims
- •The biochemical changes induced by serum incubation (higher IL-1Ra) did not prevent cartilage matrix degradation in laboratory conditions, suggesting limited protective mechanisms
- •While this is an in vitro study with limited direct clinical translation, practitioners should remain cautious about expecting dramatic anti-inflammatory effects from ACS treatments based on current evidence
Key Findings
- •Conditioned serum (PCS) showed significantly higher IL-1Ra concentration than control serum (PS), but this did not translate to protective effects on chondrocytes
- •In chondrocyte pellets stimulated with IL-1β, both PS24h and PCS treatments resulted in downregulation of cartilage matrix molecules (aggrecan and collagens) compared to untreated controls
- •Inflammation and cartilage degradation-related genes were upregulated after 48 hours in all serum-treated groups versus untreated controls
- •In cartilage explants with structural osteoarthritis, OARSI histological scores at day 24 showed no significant difference between treatment groups (PS, PCS, or untreated)